ReviewMedScience2026
On the 50th year responding to Ebola: mapping diagnostic, vaccine, and therapeutic gaps across ebolavirus species.
Review in MedScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This year marks the 50th anniversary of the Ebola virus identification, but the 2026 outbreak of Bundibugyo ebolavirus disease has exposed important limitations in Ebola preparedness strategies that remain largely focused on Zaire ebolavirus. Although major advances in diagnostics, vaccines, and therapeutics have followed the 2014-2016 West African Ebola epidemic, most licensed countermeasures were developed against Zaire ebolavirus and may provide limited protection against other ebolavirus species, including Bundibugyo ebolavirus. Herein, we examine the epidemiological significance of Bundibugyo ebolavirus and review current and emerging diagnostics, vaccines, antibody therapies, and antiviral strategies, with emphasis on their species coverage and limitations. We further discuss how diagnostic blind spots and limited species-inclusive countermeasures contributed to challenges during the current outbreak. Future Ebola preparedness should adopt a broader framework encompassing multiple ebolavirus species with epidemic potential.
Indexed as
Identifiers
42560595What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.